ReviewAdvances in medical sciences2020
The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors.
Review in Advances in medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Single-Cell and Spatial Transcriptomics Reframe the Immunosuppressive Microenvironment of Neuroendocrine Neoplasms.Cancers · 2026Review
- Prognostic and Predictive Significance of Selected Gene Mutations in Pancreatic and Intestinal Neuroendocrine Tumors.International journal of molecular sciences · 2026Review
- Socioeconomic impact of artificial intelligence-driven point-of-care testing devices for liquid biopsy in the OncoCheck system.Cancer metastasis reviews · 2025Review
- Clinical application of targeted α-emitter therapy in gastroenteropancreatic neuroendocrine neoplasms.Journal of gastroenterology · 2025Review
- Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers.Journal of neuroendocrinology · 2025Review
- Role ofFrontiers in medicine · 2025Article
- Review
- The Clinicopathological Characteristics and Surgical Treatment of Gastrointestinal Neuroendocrine Neoplasm-A 10-Year Single-Center Experience.Journal of clinical medicine · 2024Article
- Biochemical Markers for Neuroendocrine Tumors: Traditional Circulating Markers and Recent Development-A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2024Review
- Serum β-hCG as a Biomarker in Pancreatic Neuroendocrine Tumors: Rethinking Single-Analyte Approach.Cancers · 2024Article
- Evaluating Prognosis of Gastrointestinal Metastatic Neuroendocrine Tumors: Constructing a Novel Prognostic Nomogram Based on NETPET Score and Metabolic Parameters from PET/CT Imaging.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Does gamma-glutamyltransferase correlate with liver tumor burden in neuroendocrine tumors?Endocrine · 2024Article
- Enhancing precision: A predictive model forTheranostics · 2024Article
- The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective.Current treatment options in oncology · 2023Review
- PET/MRI imaging in neuroendocrine neoplasm.Abdominal radiology (New York) · 2023Review
- An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide.Diagnostics (Basel, Switzerland) · 2023Review
- Immuno-histochemical correlation of fibrosis-related markers with the desmoplastic reaction of the mesentery in small intestine neuroendocrine neoplasms.Journal of cancer research and clinical oncology · 2023Article
- Emerging Immunotherapeutic and Diagnostic Modalities in Carcinoid Tumors.Molecules (Basel, Switzerland) · 2023Review
- PET/CT and PET/MRI in neuroendocrine neoplasms.Abdominal radiology (New York) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThere are few effective biomarkers for neuroendocrine tumors. Precision oncology strategies have provided liquid biopsies for real-time and tailored decision-making. This has led to the development of the first neuroendocrine tumor liquid biopsy (the NETest). The NETest represents a transcriptomic signature of neuroendocrine tumor (NETs) that captures tumor biology and disease activity. The data have direct clinical application in terms of identifying residual disease, disease progress and the efficacy of treatment. In this overview we assess the available published information on the metrics and clinical efficacy of the NETest. MATERIAL AND
methodsPublished data on the NETest have been collated and analyzed to understand the clinical application of this multianalyte biomarker in NETs.
resultsNETest assay has been validated as a standardized and reproducible clinical laboratory measurement. It is not affected by demographic characteristics, or acid suppressive medication. Clinical utility of the NETest has been documented in gastroenteropancreatic, bronchopulmonary NETs, in paragangliomas and pheochromocytomas. The test facilitates accurate diagnosis of a NET disease, and real-time monitoring of the disease status (stable/progressive disease). It predicts aggressive tumor behavior, identifies operative tumor resection, and efficacy of the medical treatment (e.g. somatostatin analogues), or peptide receptor radionuclide therapy (PRRT). NETest metrics and clinical applications out-perform standard biomarkers like chromogranin A.
conclusionsThe NETest exhibits clinically competent metrics as an effective biomarker for neuroendocrine tumors. Measurement of NET transcripts in blood is a significant advance in neuroendocrine tumor management and demonstrates that blood provides a viable source to identify and monitor tumor status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.